🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ANTHEM BIOSCIENCES LTD ANTHEM NIFTY_MIDNSEPHARMA

Healthcare · Biotechnology · India
https://anthembio.com
Company Profile ↓
₹934.05
+25.96% 1Y
Mkt Cap₹52,466.88 Cr
P/E89.55
P/B15.53
Div. Yield0.24%
52W High₹950.70
52W Low₹590.86
Book Value₹54.16
EPS (TTM)₹10.43

Company Overview

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 26.8%.

Consistent Profit Growth

Net profit has compounded at 15.4% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 26.2% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 27.9%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,124.33 Cr (+15.2% YoY); net profit ₹591.79 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +15.2%, earnings +31.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 26.2%, profit CAGR 15.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:26.20%
1 Year:15.17%

Compounded Profit Growth

5 Years:15.39%
1 Year:31.14%

Stock Price Performance

1 Year:+25.96%
6 Months:+41.21%
3 Months:+20.33%
1 Month:+13.13%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 95% of range
₹590.86 ₹950.70
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)64.81 · Neutral
Price Performance
1M+13.13%
3M+20.33%
6M+41.21%
1Y+25.96%
Valuation vs Sector

P/E of 89.55 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 26.8%.
  • Excellent profit margin of 27.9%.
  • Compounding revenue at 26.2% over 5 years.
  • Profit CAGR of 15.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 89.5.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
89.55
Industry PE
41.64
Forward P/E
61.18
PEG Ratio
-
Book Value
₹54.16
Price to Book
15.53
P/S
23.53
EV/EBITDA
57.46
Dividend Yield
0.24%

Growth (CAGR)

Revenue 5Y
26.20%
Profit 5Y
15.39%
Revenue (YoY)
15.17%
Earnings (YoY)
31.14%

Profitability & Returns

ROCE
26.77%
ROE
19.45%
ROA
17.26%
Profit Margin
27.86%
Op Margin
33.20%
Gross Margin
61.76%
EPS (Latest Qtr)
₹2.11
EPS (TTM)
₹10.43

Balance Sheet & Liquidity

Debt/Equity
1.77
Quick Ratio
5.15
Current Ratio
5.54
Debt
₹53.92 Cr
Total Assets
₹3,429.29 Cr
Current Assets
₹1,803.14 Cr
Working Capital
₹1,477.43 Cr

Ownership

Promoter Holding
84.13%
Chg in Prom Hold
-0.05%
FII / Inst Holding
12.77%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
₹52,466.88 Cr
Total Revenue (TTM)
₹2,124.33 Cr
EBITDA
₹964.85 Cr
Free Cash Flow
₹633.32 Cr
Operating Cash Flow
₹844.49 Cr
Shares Outstanding
₹56.17 Cr
Gross Margin
61.76%
Payout Ratio
19.76%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA 934.05 89.55 ₹52,466.88 Cr 0.24% 26.77% 19.45% 26.20% 15.39%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 339.00 Cr-497.81 Cr483.20 Cr540.21 Cr550.03 Cr423.15 Cr610.94 Cr418.22 Cr
Cost of Revenue --232.71 Cr176.85 Cr230.88 Cr223.36 Cr142.59 Cr215.46 Cr146.20 Cr
Gross Profit --265.10 Cr306.35 Cr309.33 Cr326.67 Cr280.56 Cr395.49 Cr272.02 Cr
Operating Expenses 218.00 Cr-125.87 Cr141.58 Cr144.29 Cr142.26 Cr157.90 Cr167.86 Cr151.44 Cr
Operating Income 102.00 Cr-139.23 Cr164.77 Cr165.05 Cr184.40 Cr122.67 Cr227.62 Cr120.58 Cr
EBITDA 121.00 Cr-183.88 Cr209.25 Cr214.30 Cr266.13 Cr165.36 Cr319.41 Cr175.46 Cr
Interest Expense 4.00 Cr-2.55 Cr52.10 L1.61 Cr3.03 Cr35.20 L1.90 Cr88.70 L
Pretax Income 118.00 Cr-161.05 Cr178.31 Cr186.25 Cr229.60 Cr130.47 Cr277.92 Cr144.58 Cr
Tax Provision 35.40 Cr-36.72 Cr95.69 Cr50.46 Cr56.17 Cr37.66 Cr88.16 Cr24.64 Cr
Net Income 82.00 Cr-124.33 Cr82.62 Cr135.79 Cr173.43 Cr92.82 Cr189.76 Cr119.94 Cr
Diluted EPS 1.47-2.211.472.423.061.643.342.11

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 633.00 Cr1,103.00 Cr-1,056.92 Cr1,419.37 Cr1,844.55 Cr2,124.33 Cr
Cost of Revenue ---339.28 Cr599.55 Cr743.91 Cr812.28 Cr
Gross Profit ---717.65 Cr819.82 Cr1,100.64 Cr1,312.05 Cr
Operating Expenses 451.00 Cr695.00 Cr-345.95 Cr395.19 Cr508.49 Cr606.79 Cr
Operating Income 120.00 Cr346.00 Cr-371.70 Cr424.63 Cr592.15 Cr705.26 Cr
EBITDA 182.00 Cr408.00 Cr-569.27 Cr568.42 Cr756.25 Cr964.85 Cr
Interest Expense 20.00 Cr17.00 Cr-8.20 Cr9.28 Cr10.02 Cr6.54 Cr
Pretax Income 121.00 Cr366.00 Cr-497.30 Cr477.32 Cr656.87 Cr824.24 Cr
Tax Provision 27.83 Cr95.16 Cr-112.11 Cr110.01 Cr205.61 Cr232.45 Cr
Net Income 93.00 Cr271.00 Cr-385.19 Cr367.31 Cr451.26 Cr591.79 Cr
Diluted EPS 110.62319.74-6.866.548.0410.43

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 787.00 Cr1,034.00 Cr-2,014.46 Cr2,398.11 Cr2,807.58 Cr3,429.29 Cr
Current Assets ---1,323.17 Cr1,481.55 Cr1,488.17 Cr1,803.14 Cr
Cash & Equivalents ---342.24 Cr183.86 Cr171.44 Cr272.91 Cr
Inventory ---129.42 Cr211.35 Cr340.43 Cr124.52 Cr
Receivables ---274.07 Cr490.45 Cr450.40 Cr590.59 Cr
Total Liabilities ---273.79 Cr473.46 Cr397.72 Cr386.77 Cr
Current Liabilities ---163.87 Cr338.63 Cr326.23 Cr325.71 Cr
Long Term Debt ---96.19 Cr111.66 Cr47.03 Cr27.73 Cr
Total Debt 159.00 Cr100.00 Cr-126.15 Cr238.52 Cr113.32 Cr53.92 Cr
Total Equity 421.00 Cr701.00 Cr-1,740.67 Cr1,924.65 Cr2,409.86 Cr3,042.52 Cr
Shares Outstanding ---56.16 Cr56.16 Cr56.16 Cr56.17 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 166.00 Cr278.00 Cr-305.99 Cr140.15 Cr270.55 Cr844.49 Cr
Investing Cash Flow -109.00 Cr-196.00 Cr--376.02 Cr-221.46 Cr-146.56 Cr-701.62 Cr
Financing Cash Flow -48.00 Cr-63.00 Cr-63.97 Cr-77.18 Cr-135.65 Cr-40.00 Cr
Capital Expenditure -47.00 Cr-119.00 Cr--194.55 Cr-297.19 Cr-261.21 Cr-211.17 Cr
Free Cash Flow 119.00 Cr159.00 Cr-111.44 Cr-157.03 Cr9.34 Cr633.32 Cr
Net Change in Cash 9.00 Cr18.00 Cr--6.06 Cr-158.49 Cr-11.66 Cr102.87 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---67.9%57.8%59.7%61.8%
Operating Margin % 19.0%31.4%-35.2%29.9%32.1%33.2%
Net Margin % 14.7%24.6%-36.4%25.9%24.5%27.9%
ROE % 22.1%38.7%-22.1%19.1%18.7%19.5%
ROCE % ---20.1%20.6%23.9%22.7%

Shareholding Pattern

Insiders
84.13%
Institutions
12.77%
Public Float
80.46%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANTHEM

Yahoo Finance Fri, 24 Jul 2026

Anthem Biosciences Ltd (NSE:ANTHEM) Q1 2027 Earnings Call Highlights: Strong EBITDA Margin Amid ...

Anthem Biosciences Ltd (NSE:ANTHEM) reports robust operational efficiency with a 39.6% EBITDA margin, despite facing revenue timing shifts and regulatory hurdles.

Yahoo Finance Wed, 17 Jun 2026

The Healthcare M&A Wave

In this week’s edition of InnovationRx, we look at biotech M&A, the rise of India’s Anthem Biosciences, and more.

Yahoo Finance hu, 21 May 2026

Anthem Biosciences Ltd (NSE:ANTHEM) Q4 2026 Earnings Call Highlights: Record Growth and ...

Anthem Biosciences Ltd (NSE:ANTHEM) reports robust financial performance with significant revenue growth and strategic investments for future capacity expansion.

Yahoo Finance Sat, 14 Feb 2026

Anthem Biosciences Ltd (NSE:ANTHEM) Q3 2025 Earnings Call Highlights: Strong EBITDA Growth ...

Anthem Biosciences Ltd (NSE:ANTHEM) reports robust EBITDA margins and strategic growth plans despite facing market challenges and exceptional costs.

ANTHEM — Frequently Asked Questions

What is the current share price of ANTHEM BIOSCIENCES LTD (ANTHEM)?

As of 2026-09-08 04:53 IST, ANTHEM BIOSCIENCES LTD (ANTHEM) trades at ₹934.05 on NSE. Its 52-week range is ₹590.86 to ₹950.70.

What is the market capitalisation of ANTHEM?

ANTHEM BIOSCIENCES LTD (ANTHEM) has a market capitalisation of ₹52,466.88 Cr on NSE.

What is the P/E ratio of ANTHEM?

ANTHEM trades at a trailing price-to-earnings (P/E) ratio of 89.55. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 15.53.

Does ANTHEM pay a dividend?

ANTHEM BIOSCIENCES LTD (ANTHEM) currently offers a dividend yield of 0.24%.

What is the return on equity (ROE) of ANTHEM?

ANTHEM has a return on equity (ROE) of 19.45%. Its return on capital employed (ROCE) is 26.77%.

Is ANTHEM a good stock to buy?

This page provides a data-driven analysis of ANTHEM BIOSCIENCES LTD (ANTHEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space